+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dermatology Drugs Market by Treatment, by Drug, by Therapy Area, by Prescription Mode, by Distribution Channel, by End User, by Geography - Global Market Size, Share, Development, Growth, and Demand Forecast, 2013-2023

  • ID: 4749631
  • Report
  • Region: Global
  • 247 pages
  • Prescient & Strategic Intelligence Private Limited
1 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • GlaxoSmithKline plc
  • LEO Pharma A/S
  • Mylan N.V.
  • Novartis AG
  • MORE
Dermatology drugs market is expected to reach $34.5 billion by 2023, increasing personal spending, strong pipeline of dermatological drugs, and growing awareness about skin diseases are the key factors boosting the demand for dermatology drugs globally.

On the basis of treatment, the dermatology drugs market has been categorized into topical corticosteroids, retinoids, biologics, calcineurin inhibitors, antihistamines, hormonal therapy, and others. Among these, biologics is expected to be the fastest growing category, advancing at CAGR of 9.1% during the forecast period.

Based on drug, the dermatology drugs market has been mainly classified into Humira, Remicade, Otezla, Stelara, Enbrel, Cosentyx, Neoral, Taltz, Cubicin, Canesten, Zyvox, Dupixent, Protopic, Valtrex, and Eucrisa. Of these, Humira witnessed the highest demand in the market, majorly among patients suffering from psoriasis.

Major therapy areas of dermatology drugs include psoriasis, atopic dermatitis, acne, rosacea, acne scars, and skin cancer. The dermatology drugs market saw the highest revenue generated from psoriasis drugs during the historical period. The category generated revenue of $14.2 billion in the market in 2017. The report also provides the analysis of various therapy areas, on the basis of prescription mode.

On the basis of prescription mode, the market has been categorized into OTC and prescription-based drugs, of which the drugs sold through prescriptions held a significant market share in 2017.

On the basis of distribution channel, the dermatology drugs market has been categorized into direct, wholesale/retail, and online channels. Of these, the fastest growth in the market during the forecast period is expected from direct distribution channels, with 8.5% CAGR. Besides, the major end users covered under the scope of the study are hospitals, clinics, cosmetic centers, and at-home users, where hospitals generated the highest revenue, amounting to $8.2 billion, in the market in 2017. This can be attributed to the availability of improved healthcare facilities and rising patient base in hospitals globally.

During the forecast period, the dermatology drugs market is forecasted to witness the fastest growth in APAC, with 9.6% CAGR. This growth can be attributed to the increasing disposable income of people in the region, which is leading to the high adoption of skincare products, including dermatological drugs. Moreover, the increase in the number of skin cancer cases in the region is contributing to the high demand for these drugs.

Furthermore, several market players, as part of their business strategy, are exploring the untapped market in developing economies such as China and India, which, in turn, is supporting the growth of the APAC dermatology drugs market. For instance, in October 2017, Glenmark Pharmaceuticals Ltd., an Indian pharmaceutical manufacturer, received approval from the Drug Controller General of India to launch Otezla, a new class of oral medication for psoriasis, after conducting clinical trials on psoriasis patients for 16 weeks. The approval and launch of new medications in developing countries are expected to boost the demand for dermatological drugs in APAC during the forecast period.

Companies operating in the dermatology drugs market are collaborating with other pharmaceutical firms to develop new and innovative products. For instance, in November 2018, Sanofi collaborated with Denali Therapeutics Inc. (Denali), a biopharmaceutical company, for the development of multiple molecules, DNL747 and DNL758, with the potential to treat a range of neurological and systemic inflammatory diseases. Under the agreement, Sanofi will pay $125 million to Denali to study the lead molecule DNL747 in multiple sclerosis, Alzheimer’s disease, and amyotrophic lateral sclerosis and DNL758 in systemic inflammatory diseases, such as rheumatoid arthritis and psoriasis.

In July 2018, Novartis AG entered into a license agreement with Galapagos NV (Belgium) and MorphoSys AG (Germany), two biotech companies, for their compound MOR106. Under the agreement, Novartis agreed to make an upfront payment of $110.6 (EUR 95) million to Galapagos and MorphoSys to acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications.

Some of the other key players in the dermatology drugs market are Celgene Corporation, Bausch Health Companies Inc., Pfizer Inc., Bristol-Myers Squibb Company, Johnson & Johnson, Allergan plc, Merck & Co. Inc., Amgen Inc., AbbVie Inc., Eli Lilly and Company, Nestlé Skin Health S.A., GlaxoSmithKline plc, Mylan N.V., and LEO Pharma A/S.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc.
  • Amgen Inc.
  • GlaxoSmithKline plc
  • LEO Pharma A/S
  • Mylan N.V.
  • Novartis AG
  • MORE
Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation by Treatment
1.3.2 Market Segmentation by Drug
1.3.3 Market Segmentation by Prescription Mode
1.3.4 Market Segmentation by Therapy Area
1.3.5 Market Segmentation by Distribution Channel
1.3.6 Market Segmentation by End User
1.3.7 Market Segmentation by Geography
1.3.8 Analysis Period
1.3.9 Market Data Reporting Unit
1.3.9.1 Value
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By region
2.2.1.2 By industry participant
2.2.1.3 By company type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Assumptions for the Study

Chapter 3. Executive Summary

Chapter 4. Introduction
4.1 Definition of Market Segments
4.1.1 By Treatment
4.1.1.1 Topical corticosteroids
4.1.1.2 Retinoids
4.1.1.3 Biologics
4.1.1.4 Calcineurin inhibitors
4.1.1.5 Antihistamines
4.1.1.6 Hormonal therapy
4.1.1.7 Others
4.1.2 By Drug
4.1.2.1 Humira
4.1.2.2 Remicade
4.1.2.3 Otezla
4.1.2.4 Stelara
4.1.2.5 Enbrel
4.1.2.6 Cosentyx
4.1.2.7 Neoral
4.1.2.8 Taltz
4.1.2.9 Cubicin
4.1.2.10 Canesten
4.1.2.11 Zyvox
4.1.2.12 Dupixent
4.1.2.13 Protopic
4.1.2.14 Valtrex
4.1.2.15 Eucrisa
4.1.2.16 Others
4.1.3 By Prescription Mode
4.1.3.1 Prescription-based drugs
4.1.3.2 Over-the-counter (OTC) drugs
4.1.4 By Therapy Area
4.1.4.1 Psoriasis
4.1.4.2 Atopic dermatitis
4.1.4.3 Acne
4.1.4.4 Rosacea
4.1.4.5 Acne scars
4.1.4.6 Skin cancer
4.1.4.7 Others
4.1.5 By Distribution Channel
4.1.5.1 Direct
4.1.5.2 Wholesale/retail
4.1.5.3 Online
4.1.6 By End User
4.1.6.1 Hospitals
4.1.6.2 Clinics
4.1.6.3 Cosmetic centers
4.1.6.4 At-home
4.1.6.5 Others
4.2 Market Dynamics
4.2.1 Trends
4.2.1.1 Growing number of product approvals
4.2.2 Drivers
4.2.2.1 Rising geriatric population
4.2.2.2 Increasing incidence of dermatological diseases
4.2.2.3 Growing awareness on skin diseases
4.2.2.4 Increasing personal spending
4.2.2.5 Strong pipeline for dermatological drugs
4.2.2.6 Impact analysis of drivers on market forecast
4.2.3 Restraints
4.2.3.1 Patent expiry and generic drug development
4.2.3.2 Side-effects of certain classes of therapeutic drugs
4.2.3.3 Impact analysis of restraints on market forecast
4.2.4 Opportunities
4.2.4.1 Huge potential in emerging markets
4.3 Porter’s Five Forces Analysis

Chapter 5. Global Market Size and Forecast
5.1 By Treatment
5.2 By Drug
5.3 By Prescription Mode
5.4 By Therapy Area
5.4.1 Psoriasis Dermatology Drugs Market, by Prescription Mode
5.4.2 Atopic Dermatitis Dermatology Drugs Market, by Prescription Mode
5.4.3 Acne Dermatology Drugs Market, by Prescription Mode
5.4.4 Rosacea Dermatology Drugs Market, by Prescription Mode
5.4.5 Acne Scars Dermatology Drugs Market, by Prescription Mode
5.4.6 Skin Cancer Dermatology Drugs Market, by Prescription Mode
5.5 By Distribution Channel
5.6 By End User
5.7 By Region

Chapter 6. North America Market Size and Forecast
6.1 By Treatment
6.2 By Prescription Mode
6.3 By Therapy Area
6.3.1 Psoriasis Dermatology Drugs Market, by Prescription Mode
6.3.2 Atopic Dermatitis Dermatology Drugs Market, by Prescription Mode
6.3.3 Acne Dermatology Drugs Market, by Prescription Mode
6.3.4 Rosacea Dermatology Drugs Market, by Prescription Mode
6.3.5 Acne Scars Dermatology Drugs Market, by Prescription Mode
6.3.6 Skin Cancer Dermatology Drugs Market, by Prescription Mode
6.4 By Distribution Channel
6.5 By End User
6.6 By Country

Chapter 7. Europe Market Size and Forecast
7.1 By Treatment
7.2 By Prescription Mode
7.3 By Therapy Area
7.3.1 Psoriasis Dermatology Drugs Market, by Prescription Mode
7.3.2 Atopic Dermatitis Dermatology Drugs Market, by Prescription Mode
7.3.3 Acne Dermatology Drugs Market, by Prescription Mode
7.3.4 Rosacea Dermatology Drugs Market, by Prescription Mode
7.3.5 Acne Scars Dermatology Drugs Market, by Prescription Mode
7.3.6 Skin Cancer Dermatology Drugs Market, by Prescription Mode
7.4 By Distribution Channel
7.5 By End User
7.6 By Country

Chapter 8. APAC Market Size and Forecast
8.1 By Treatment
8.2 By Prescription Mode
8.3 By Therapy Area
8.3.1 Psoriasis Dermatology Drugs Market, by Prescription Mode
8.3.2 Atopic Dermatitis Dermatology Drugs Market, by Prescription Mode
8.3.3 Acne Dermatology Drugs Market, by Prescription Mode
8.3.4 Rosacea Dermatology Drugs Market, by Prescription Mode
8.3.5 Acne Scars Dermatology Drugs Market, by Prescription Mode
8.3.6 Skin Cancer Dermatology Drugs Market, by Prescription Mode
8.4 By Distribution Channel
8.5 By End User
8.6 By Country

Chapter 9. LATAM Market Size and Forecast
9.1 By Treatment
9.2 By Prescription Mode
9.3 By Therapy Area
9.3.1 Psoriasis Dermatology Drugs Market, by Prescription Mode
9.3.2 Atopic Dermatitis Dermatology Drugs Market, by Prescription Mode
9.3.3 Acne Dermatology Drugs Market, by Prescription Mode
9.3.4 Rosacea Dermatology Drugs Market, by Prescription Mode
9.3.5 Acne Scars Dermatology Drugs Market, by Prescription Mode
9.3.6 Skin Cancer Dermatology Drugs Market, by Prescription Mode
9.4 By Distribution Channel
9.5 By End User
9.6 By Country

Chapter 10. MEA Market Size and Forecast
10.1 By Treatment
10.2 By Prescription Mode
10.3 By Therapy Area
10.3.1 Psoriasis Dermatology Drugs Market, by Prescription Mode
10.3.2 Atopic Dermatitis Dermatology Drugs Market, by Prescription Mode
10.3.3 Acne Dermatology Drugs Market, by Prescription Mode
10.3.4 Rosacea Dermatology Drugs Market, by Prescription Mode
10.3.5 Acne Scars Dermatology Drugs Market, by Prescription Mode
10.3.6 Skin Cancer Dermatology Drugs Market, by Prescription Mode
10.4 By Distribution Channel
10.5 By End User

Chapter 11. Competitive Landscape
11.1 Product Benchmarking of Some Key Players
11.2 Global Strategic Developments of Key Players
11.2.1 Product Launches/Approvals
11.2.2 Partnerships and Collaborations
11.2.3 Acquisitions
11.2.4 Development Results
11.2.5 Other Developments

Chapter 12. Company Profiles
12.1 Celgene Corporation
12.1.1 Business Overview
12.1.2 Product and Service Offerings
12.1.3 Key Financial Summary
12.2 Bausch Health Companies Inc.
12.2.1 Business Overview
12.2.2 Product and Service Offerings
12.2.3 Key Financial Summary
12.3 Novartis AG
12.3.1 Business Overview
12.3.2 Product and Service Offerings
12.3.3 Key Financial Summary
12.4 Pfizer Inc.
12.4.1 Business Overview
12.4.2 Product and Service Offerings
12.4.3 Key Financial Summary
12.5 Bristol-Myers Squibb Company
12.5.1 Business Overview
12.5.2 Product and Service Offerings
12.5.3 Key Financial Summary
12.6 Johnson & Johnson
12.6.1 Business Overview
12.6.2 Product and Service Offerings
12.6.3 Key Financial Summary
12.7 Allergan plc
12.7.1 Business Overview
12.7.2 Product and Service Offerings
12.7.3 Key Financial Summary
12.8 Merck & Co. Inc.
12.8.1 Business Overview
12.8.2 Product and Service Offerings
12.8.3 Key Financial Summary
12.9 Amgen Inc.
12.9.1 Business Overview
12.9.2 Product and Service Offerings
12.9.3 Key Financial Summary
12.10 AbbVie Inc.
12.10.1 Business Overview
12.10.2 Product and Service Offerings
12.10.3 Key Financial Summary
12.11 Eli Lilly and Company
12.11.1 Business Overview
12.11.2 Product and Service Offerings
12.11.3 Key Financial Summary
12.12 Sanofi
12.12.1 Business Overview
12.12.2 Product and Service Offerings
12.12.3 Key Financial Summary
12.13 Nestlé Skin Health S.A.
12.13.1 Business Overview
12.13.2 Product and Service Offerings
12.14 GlaxoSmithKline plc
12.14.1 Business Overview
12.14.2 Product and Service Offerings
12.14.2.1 Marketed products
12.14.2.2 Pipeline products
12.14.3 Key Financial Summary
12.15 Mylan N.V.
12.15.1 Business Overview
12.15.2 Product and Service Offerings
12.15.3 Key Financial Summary
12.16 LEO Pharma A/S
12.16.1 Business Overview
12.16.2 Product and Service Offerings
12.16.3 Key Financial Summary

Chapter 13. Appendix
13.1 Abbreviations
13.2 Sources and References
13.3 Related Reports

List of Tables
TABLE 1 ANALYSIS PERIOD OF THE STUDY
TABLE 2 PIPELINE DRUGS FOR THE TREATMENT OF ACNE
TABLE 3 PIPELINE DRUGS FOR THE TREATMENT OF ACTINIC KERATOSIS
TABLE 4 DRIVERS FOR THE MARKET: IMPACT ANALYSIS
TABLE 5 PATENT EXPIRATION OF DERMATOLOGY DRUGS
TABLE 6 RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS
TABLE 7 GLOBAL DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2017)
TABLE 8 GLOBAL DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2018-2023)
TABLE 9 GLOBAL DERMATOLOGY DRUGS MARKET, BY DRUG, $M (2013-2017)
TABLE 10 GLOBAL DERMATOLOGY DRUGS MARKET, BY DRUG, $M (2018-2023)
TABLE 11 GLOBAL DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 12 GLOBAL DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 13 GLOBAL DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2017)
TABLE 14 GLOBAL DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2018-2023)
TABLE 15 GLOBAL PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 16 GLOBAL PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 17 GLOBAL ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 18 GLOBAL ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 19 GLOBAL ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 20 GLOBAL ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 21 GLOBAL ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 22 GLOBAL ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 23 GLOBAL ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 24 GLOBAL ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 25 GLOBAL SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 26 GLOBAL SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 27 GLOBAL DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2017)
TABLE 28 GLOBAL DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2018-2023)
TABLE 29 GLOBAL DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2017)
TABLE 30 GLOBAL DERMATOLOGY DRUGS MARKET, BY END USER, $M (2018-2023)
TABLE 31 GLOBAL DERMATOLOGY DRUGS MARKET, BY REGION, $M (2013-2017)
TABLE 32 GLOBAL DERMATOLOGY DRUGS MARKET, BY REGION, $M (2018-2023)
TABLE 33 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2017)
TABLE 34 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2018-2023)
TABLE 35 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 36 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 37 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2017)
TABLE 38 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2018-2023)
TABLE 39 NORTH AMERICA PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 40 NORTH AMERICA PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 41 NORTH AMERICA ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 42 NORTH AMERICA ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 43 NORTH AMERICA ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 44 NORTH AMERICA ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 45 NORTH AMERICA ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 46 NORTH AMERICA ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 47 NORTH AMERICA ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 48 NORTH AMERICA ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 49 NORTH AMERICA SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 50 NORTH AMERICA SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 51 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2017)
TABLE 52 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2018-2023)
TABLE 53 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2017)
TABLE 54 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY END USER, $M (2018-2023)
TABLE 55 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2013-2017)
TABLE 56 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2018-2023)
TABLE 57 EUROPE DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2017)
TABLE 58 EUROPE DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2018-2023)
TABLE 59 EUROPE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 60 EUROPE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 61 EUROPE DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2017)
TABLE 62 EUROPE DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2018-2023)
TABLE 63 EUROPE PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 64 EUROPE PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 65 EUROPE ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 66 EUROPE ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 67 EUROPE ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 68 EUROPE ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 69 EUROPE ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 70 EUROPE ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 71 EUROPE ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 72 EUROPE ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 73 EUROPE SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 74 EUROPE SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 75 EUROPE DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2017)
TABLE 76 EUROPE DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2018-2023)
TABLE 77 EUROPE DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2017)
TABLE 78 EUROPE DERMATOLOGY DRUGS MARKET, BY END USER, $M (2018-2023)
TABLE 79 EUROPE DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2013-2017)
TABLE 80 EUROPE DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2018-2023)
TABLE 81 APAC DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2017)
TABLE 82 APAC DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2018-2023)
TABLE 83 APAC DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 84 APAC DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 85 APAC DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2017)
TABLE 86 APAC DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2018-2023)
TABLE 87 APAC PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 88 APAC PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 89 APAC ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 90 APAC ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 91 APAC ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 92 APAC ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 93 APAC ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 94 APAC ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 95 APAC ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 96 APAC ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 97 APAC SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 98 APAC SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 99 APAC DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2017)
TABLE 100 APAC DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2018-2023)
TABLE 101 APAC DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2017)
TABLE 102 APAC DERMATOLOGY DRUGS MARKET, BY END USER, $M (2018-2023)
TABLE 103 APAC DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2013-2017)
TABLE 104 APAC DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2018-2023)
TABLE 105 LATAM DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2017)
TABLE 106 LATAM DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2018-2023)
TABLE 107 LATAM DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 108 LATAM DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 109 LATAM DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2017)
TABLE 110 LATAM DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2018-2023)
TABLE 111 LATAM PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 112 LATAM PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 113 LATAM ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 114 LATAM ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 115 LATAM ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 116 LATAM ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 117 LATAM ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 118 LATAM ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 119 LATAM ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 120 LATAM ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 121 LATAM SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 122 LATAM SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 123 LATAM DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2017)
TABLE 124 LATAM DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2018-2023)
TABLE 125 LATAM DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2017)
TABLE 126 LATAM DERMATOLOGY DRUGS MARKET, BY END USER, $M (2018-2023)
TABLE 127 LATAM DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2013-2017)
TABLE 128 LATAM DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2018-2023)
TABLE 129 MEA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2017)
TABLE 130 MEA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2018-2023)
TABLE 131 MEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 132 MEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 133 MEA DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2017)
TABLE 134 MEA DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2018-2023)
TABLE 135 MEA PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 136 MEA PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 137 MEA ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 138 MEA ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 139 MEA ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 140 MEA ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 141 MEA ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 142 MEA ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 143 MEA ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 144 MEA ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 145 MEA SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2017)
TABLE 146 MEA SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2018-2023)
TABLE 147 MEA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2017)
TABLE 148 MEA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2018-2023)
TABLE 149 MEA DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2017)
TABLE 150 MEA DERMATOLOGY DRUGS MARKET, BY END USER, $M (2018-2023)
TABLE 151 CELGENE CORPORATION - AT A GLANCE
TABLE 152 CELGENE CORPORATION - KEY FINANCIAL SUMMARY
TABLE 153 BAUSCH HEALTH COMPANIES INC. - AT A GLANCE
TABLE 154 BAUSCH HEALTH COMPANIES INC. - KEY FINANCIAL SUMMARY
TABLE 155 NOVARTIS AG - AT A GLANCE
TABLE 156 NOVARTIS AG - KEY FINANCIAL SUMMARY
TABLE 157 PFIZER INC. - AT A GLANCE
TABLE 158 PFIZER INC. - KEY FINANCIAL SUMMARY
TABLE 159 BRISTOL-MYERS SQUIBB COMPANY - AT A GLANCE
TABLE 160 BRISTOL-MYERS SQUIBB COMPANY - KEY FINANCIAL SUMMARY
TABLE 161 JOHNSON & JOHNSON - AT A GLANCE
TABLE 162 JOHNSON & JOHNSON - KEY FINANCIAL SUMMARY
TABLE 163 ALLERGAN PLC - AT A GLANCE
TABLE 164 ALLERGAN PLC - KEY FINANCIAL SUMMARY
TABLE 165 MERCK & CO. INC. - AT A GLANCE
TABLE 166 MERCK & CO. INC. - KEY FINANCIAL SUMMARY
TABLE 167 AMGEN INC. - AT A GLANCE
TABLE 168 AMGEN INC. - KEY FINANCIAL SUMMARY
TABLE 169 AMGEN INC. - REVENUE SPLIT BY PRODUCT AND GEOGRAPHY (2017)
TABLE 170 ABBVIE INC. - AT A GLANCE
TABLE 171 ABBVIE INC. - KEY FINANCIAL SUMMARY
TABLE 172 ELI LILLY AND COMPANY - AT A GLANCE
TABLE 173 ELI LILLY AND COMPANY - KEY FINANCIAL SUMMARY
TABLE 174 SANOFI - AT A GLANCE
TABLE 175 SANOFI - KEY FINANCIAL SUMMARY
TABLE 176 NESTLÉ SKIN HEALTH S.A. - AT A GLANCE
TABLE 177 GLAXOSMITHKLINE PLC - AT A GLANCE
TABLE 178 GLAXOSMITHKLINE PLC - KEY FINANCIAL SUMMARY
TABLE 179 MYLAN N.V. - AT A GLANCE
TABLE 180 MYLAN N.V. - KEY FINANCIAL SUMMARY
TABLE 181 LEO PHARMA A/S - AT A GLANCE
TABLE 182 LEO PHARMA A/S - KEY FINANCIAL SUMMARY

List of Figures
FIG 1 RESEARCH SCOPE
FIG 2 RESEARCH METHODOLOGY
FIG 3 REGIONAL SPLIT OF PRIMARY AND SECONDARY RESEARCH
FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY REGION
FIG 5 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT
FIG 6 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE
FIG 7 DATA TRIANGULATION APPROACH
FIG 8 GLOBAL DERMATOLOGY DRUGS MARKET SUMMARY
FIG 9 BARGAINING POWER OF BUYERS
FIG 10 BARGAINING POWER OF SUPPLIERS
FIG 11 INTENSITY OF RIVALRY
FIG 12 THREAT OF NEW ENTRANTS
FIG 13 THREAT OF SUBSTITUTES
FIG 14 SNAPSHOT OF GLOBAL DERMATOLOGY DRUGS MARKET (2017)
FIG 15 GLOBAL DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2023)
FIG 16 GLOBAL DERMATOLOGY DRUGS MARKET, BY DRUG, $M (2013-2023)
FIG 17 GLOBAL DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 18 GLOBAL DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2023)
FIG 19 GLOBAL PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 20 GLOBAL ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 21 GLOBAL ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 22 GLOBAL ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 23 GLOBAL ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 24 GLOBAL SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 25 GLOBAL DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2023)
FIG 26 GLOBAL DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2023)
FIG 27 WORLDWIDE MAJOR MARKETS FOR DERMATOLOGY DRUGS
FIG 28 NORTH AMERICA DERMATOLOGY DRUGS MARKET SNAPSHOT
FIG 29 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2023)
FIG 30 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 31 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2023)
FIG 32 NORTH AMERICA PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 33 NORTH AMERICA ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 34 NORTH AMERICA ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 35 NORTH AMERICA ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 36 NORTH AMERICA ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 37 NORTH AMERICA SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 38 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2023)
FIG 39 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2023)
FIG 40 NORTH AMERICA DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2013-2023)
FIG 41 EUROPE DERMATOLOGY DRUGS MARKET SNAPSHOT
FIG 42 EUROPE DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2023)
FIG 43 EUROPE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 44 EUROPE DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2023)
FIG 45 EUROPE PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 46 EUROPE ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 47 EUROPE ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 48 EUROPE ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 49 EUROPE ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 50 EUROPE SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 51 EUROPE DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2023)
FIG 52 EUROPE DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2023)
FIG 53 EUROPE DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2013-2023)
FIG 54 APAC DERMATOLOGY DRUGS MARKET SNAPSHOT
FIG 55 APAC DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2023)
FIG 56 APAC DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 57 APAC DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2023)
FIG 58 APAC PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 59 APAC ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 60 APAC ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 61 APAC ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 62 APAC ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 63 APAC SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 64 APAC DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2023)
FIG 65 APAC DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2023)
FIG 66 APAC DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2013-2023)
FIG 67 LATAM DERMATOLOGY DRUGS MARKET SNAPSHOT
FIG 68 LATAM DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2023)
FIG 69 LATAM DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 70 LATAM DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2023)
FIG 71 LATAM PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 72 LATAM ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 73 LATAM ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 74 LATAM ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 75 LATAM ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 76 LATAM SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 77 LATAM DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2023)
FIG 78 LATAM DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2023)
FIG 79 LATAM DERMATOLOGY DRUGS MARKET, BY COUNTRY, $M (2013-2023)
FIG 80 MEA DERMATOLOGY DRUGS MARKET SNAPSHOT
FIG 81 MEA DERMATOLOGY DRUGS MARKET, BY TREATMENT, $M (2013-2023)
FIG 82 MEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 83 MEA DERMATOLOGY DRUGS MARKET, BY THERAPY AREA, $M (2013-2023)
FIG 84 MEA PSORIASIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 85 MEA ATOPIC DERMATITIS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 86 MEA ACNE DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 87 MEA ROSACEA DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 88 MEA ACNE SCARS DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 89 MEA SKIN CANCER DERMATOLOGY DRUGS MARKET, BY PRESCRIPTION MODE, $M (2013-2023)
FIG 90 MEA DERMATOLOGY DRUGS MARKET, BY DISTRIBUTION CHANNEL, $M (2013-2023)
FIG 91 MEA DERMATOLOGY DRUGS MARKET, BY END USER, $M (2013-2023)
FIG 92 PRODUCT BENCHMARKING OF SOME KEY PLAYERS
FIG 93 CELGENE CORPORATION - REVENUE SPLIT BY PRODUCT AND GEOGRAPHY (2017)
FIG 94 BAUSCH HEALTH COMPANIES INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 95 NOVARTIS AG - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 96 PFIZER INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 97 BRISTOL-MYERS SQUIBB COMPANY - REVENUE SPLIT BY BRAND AND GEOGRAPHY (2017)
FIG 98 JOHNSON & JOHNSON - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 99 ALLERGAN PLC - REVENUE SPLIT BY SEGMENT (2017)
FIG 100 MERCK & CO. INC. - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 101 ABBVIE INC. - REVENUE SPLIT BY PRODUCT AND GEOGRAPHY (2017)
FIG 102 ELI LILLY AND COMPANY - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 103 SANOFI - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 104 GLAXOSMITHKLINE PLC - REVENUE SPLIT BY SEGMENT AND GEOGRAPHY (2017)
FIG 105 MYLAN N.V. - REVENUE SPLIT BY SEGMENT (2017)
FIG 106 LEO PHARMA A/S - REVENUE SPLIT BY THERAPEUTIC AREA AND GEOGRAPHY (2017)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bausch Health Companies Inc.
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Allergan plc
  • Merck & Co. Inc.
  • Amgen Inc.
  • AbbVie Inc.
  • Eli Lilly and Company
  • Sanofi
  • Nestlé Skin Health S.A.
  • GlaxoSmithKline plc
  • Mylan N.V.
  • LEO Pharma A/S
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4749631
Adroll
adroll